A.J. Bergman
Chief Financial Officer
Replay available
Capricor Therapeutics, Inc. (CAPR) Q1 2026 Earnings Call
Capricor Therapeutics, Inc. (NASDAQ: CAPR) Q1 2026 earnings conference call, held 2026-05-12. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Linda Marban
Chief Development Officer
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Capricor Therapeutics, Inc..
Replay transcript excerpt
WEBVTT 00:00:21.277 -- 00:00:23.277 Thank 00:00:26.785 -- 00:00:28.785 you. 00:01:57.987 -- 00:01:59.809 We'll 00:01:59.809 -- 00:02:01.809 be 00:02:07.620 -- 00:02:09.620 right 00:02:12.767 -- 00:02:14.767 back. 00:02:43.718 -- 00:02:48.723 Good afternoon, ladies and gentlemen, and welcome to the Capricorn Therapeutics 00:02:48.723 -- 00:02:54.350 First Quarter 2026 Conference Call. At this time, all participant 00:02:54.350 -- 00:02:59.936 lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer 00:02:59.936 -- 00:03:05.141 session. If at any time during this call you require immediate assistance, 00:03:05.141 -- 00:03:10.627 please press star zero for the operator. This call is being recorded 00:03:10.627 -- 00:03:15.630 on Tuesday, May 12, 2026. I would now like to turn 00:03:15.630 -- 00:03:20.237 the conference over to our CFO, AJ Bergman, for the forward-looking 00:03:20.237 -- 00:03:22.658 statement. Please go ahead. 00:03:23.302 -- 00:03:27.568 Thank you, and good afternoon, everyone. Before we start, I would like to state that 00:03:27.568 -- 00:03:32.215 we will be making certain forward-looking statements during today's presentation. 00:03:32.215 -- 00:03:35.681 These statements may include statements regarding, among other things, the efficacy, 00:03:35.681 -- 00:03:40.528 safety, and intended utilization of our product candidates, potential regulatory developments 00:03:40.528 -- 00:03:45.631 involving our product candidates, our future R&D plans, our anticipated conduct and timing 00:03:45.631 -- 00:03:49.917 of preclinical and clinical studies, enrollment of patients in our clinical studies, 00:03:49.917 -- 00:03:54.743 our plans to present or report additional data, our plans regarding regulatory filings, 00:03...